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A quiet but profound revolution in theoretical framework, 
a paradigm shift, now has infused the consideration of 
therapies in autoimmune diseases and cancers, as exem- 
plified at the Jennifer Jones Simon Foundation workshop 
on Tumor Antigens as Self-Antigens, held in Los Angeles, 
California, on January 28-27, 1995. 
It is becoming accepted that a large set of antigenic 
determinants of the self have not induced self-tolerance 
(reviewed by Sercarz et al., 1993) and that these peptide 
determinants furnish target structures for autoimmune at- 
tack (reviewed by Lanzavecchia, 1995) and could provide 
potential targets for immune responses directed against 
tumors. It is not necessary to seek mysterious nonself- or 
neoself-antigens expressed by the tumor. The bulk of the 
lively and open discussion, characteristic of these free 
format workshops with no fixed presentations, was modu- 
lated very capably by A. Tobin (University of California, 
Los Angeles), a neurobiologist, and focused on how to 
initiate, maintain, and regulate antitumor autoimmunity, 
which could translate into effective treatment in cancer 
clinics. 
Are there in fact certain tumor-related determinants that 
can be rendered into crucial targets of attack by the im- 
mune system? The pertinent focus is on suitable antigen 
processing and subsequent presentation by major histo- 
compatibility complex (MHC) class I and class II molecules 
expressed by tumor cells. Any of the peptides that is bound 
in the groove of an MHC molecule on tumor cells provides 
a potential target determinant for attack by the immune 
system. The peptides bound by the MHC molecules of all 
ceils, including tumor cells, are derived from endogenous 
cellular (or viral) proteins, and the antigen-processing ma- 
chinery of the cells manages to display certain antigen 
determinants to ambient T cells. Tumor cells are distinct 
in that they possess additional oncoproteins that either 
are overexpressed owing to dysregulation or are mutated 
and have thereby conferred the tumor phenotype to these 
cells, to developmental antigens reexpressed during the 
process of tumorigenesis, or to passenger mutations in 
nononcogenic proteins that result from the loss of mecha- 
nisms that maintain genomic stability. Using T cell clones 
that are specifically able to kill the tumor as detectors for 
immunogenic tumor-derived determinants bound to MHC 
molecules of the tumor, several investigators have shown 
that T cells indeed recognize peptides from endogenous 
normal (and occasionally mutant) self-proteins. T. Boon 
and colleagues (van der Bruggen et al., 1991), in their 
pioneering studies, drew a page from bacterial genetics 
and cloned genes encoding tumor antigens recognized 
by CD8 T cells specific for human melanomas. Melanoma 
antigen 1 (MAGE-1) to MAGE-3 were the original family of 
human melanoma-specific antigens that were molecularly 
defined in this way and were followed by isolation of deter- 
minants on tyrosinase, gp100, and Melan-A-MART-1 rec- 
ognized by antimelanoma T cells (reviewed by Houghton, 
1994). It is interesting that the MAGE gene family is not 
expressed in any normal adult tissue except testis, but is 
expressed in a large proportion of other human tumors 
(including small cell lung carcinoma, breast cancers, and 
colon carcinoma) and perhaps represents developmental 
antigens reexpressed during the process of tumorigene- 
sis. Tyrosinase, gplO0, and Melan-A-MART-1 are normal 
self-proteins specific to the melanocyte lineage and T cells 
specific for determinants on each of these antigens can 
be found in a large majority of melanoma patients (re- 
viewed by Houghton, 1994; Pardoll, 1994). It is thus be- 
coming clear that there is no special group of proteins 
that can be dubbed tumor antigens, and the distinction 
between self-antigens and tumor antigens is rapidly van- 
ishing. Thus, as summed up by Tobin, we have entered 
an era in which “we either know the tumor antigens or 
know how to know them.” 
But can the immune system make a T cell response 
against all the peptides bound to MHC molecules of a 
tumor cell? Part of the answer lies in the availability of the 
Tcell repertoire membership directed against MHC-bound 
determinants and the proportion of T cells rendered toler- 
ant in each individual. It is now thought that only well- 
expressed self-determinants are efficient in tolerance in- 
duction. In addition, on every self-antigen, there are 
sequestered determinants that do not succeed in inducing 
tolerance but that, under the circumstances of severe in- 
flammation and its attendant cytokine milieu, can be dis- 
played in an immunogenic context. Among the diversity 
of self-reactive T cells that evade negative selection, tu- 
mor-specific members can be mobilized under conditions 
of heightened awareness by the immune system-in 
which MHC molecules, surface adherence molecules, and 
costimulators are up-regulated and become available for 
possibly killing interaction along with newly displayed, pre- 
viously “cryptic” self-antigenic determinants (reviewed by 
Sercarz et al., 1993; Lanzavecchia, 1995). Autoimmune 
disease on one hand and the existence of tumor-specific 
cytolytic T cells recognizing self-peptides in the cancer 
patient on theother are atestimonyto theenormouspoten- 
tial resources inherent in the positively selected T cell rep- 
ertoire, directed to the cryptic self. For example, T cells 
specific for peptides of self-protein tyrosinase can be iso- 
lated from normal individuals, which can attack and kill 
melanoma cells from human lymphocyte antigen (HLA)- 
matched cancer patients (Visseren et al., 1995). What may 
be critical is the density of the upregulated peptide 
MHC complexes, as well as the expression of costimula- 
tory signals that influence activation of the otherwise silent 
tumor-specific T cell repertoire existent in the cancer pa- 
tient. The task at hand is how to generate and manipulate 
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these signals so as to engage these antitumor, antiself T 
cells in an attack on the tumor (see below) without causing 
damage to neighboring tissue. Lessons still to be learned 
from the analogous initial stimuli that activate the hardy, 
pathogenic, self-directed responses found in autoimmu- 
nity could potentially be applied to the specific initiation 
and maintenance of response against such dangerous in- 
ternal enemies as tumors. The use of immunogenic peptide 
determinants from self-proteins that are either specifically 
expressed (for example, MAGE antigens) or overexpressed 
(for example, HER-2lneu; see below) in the tumor will pos- 
sibly activate an immune activity that exclusively damages 
the tumor. 
It is well established that the immune system gets pro- 
pelled only upon ligand recognition in a context of height- 
ened expression of costimulatory molecules, adhesion 
molecules, and HLA molecules on antigen-presenting 
cells (APCs) (as described above), or in P. Matzinger’s 
(National Institutes of Health, Bethesda, Maryland) words, 
in the context of “danger (reviewed by Matzinger, 1994). 
Adjuvants can transform a weak stimulus into one that 
signals danger, the only state to which the system has 
evolved responsiveness. If a dangerous stimulus is one 
that produces a costimulatory milieu, Listeria monocyto- 
genes works as the Paul Revere of danger, warning adju- 
vants that might render the immune system tumor-ready. 
One reason for this could be its penchant for inducing 
macrophages to produce interleukin-12 (IL-12), a cytokine 
that is a potent activator of T helper type 1 (lhl) cells 
(reviewed by Mosmann et al., 1991) and cytotoxic CD8 T 
lymphocyte cells (CTLs). In another experiment by No- 
guchi et al. (1995), a mutant peptide of p53 injected along 
with IL-12 was able to destroy completely an established 
tumor in a tumor-bearing host, whereas the same peptide 
or IL-12 akne was totally ineffective at killing the same 
tumor. J. Berzofsky (National Institutes of Health, Bethesda, 
Maryland) mentioned similar results indicating that IL-1 2’s 
remarkable effectiveness was noteworthy when used in 
vitro with normally unresponsive T cells from HIV-positive 
individuals (Clerici et al., 1993). IL-12 thus was touted as 
an ultimate weapon in tumor therapy, an “atomic missile” 
that could help initiate response in the intended direction 
with minimal side effects. Given the heterogeneity among 
tumors, different cytokines might be effective in killing dif- 
ferent tumors. 
The effectiveness of heightened expression of costimu- 
latory molecules and cytokines in antitumor immunity is 
also evident from studies using whole tumor cell vaccines. 
Genetic manipulation of tumors designed either to en- 
hance the presentation of tumor antigens or to provide 
enhanced costimulatoty signals to T cells has been a route 
adopted by immunologists to increase immunogenicity of 
whole tumor cells (reviewed by Pardoll, 1993; Moudgil and 
Sercarz, 1994). Tumor cells transfected with 87 genes to 
provide enhanced costimulation were clearly more potent 
immunogens than parent tumors. Similarly, vaccination 
with tumor cells transduced with granulocyte-macro- 
phage colony-stimulating factor (GM-CSF) induced long- 
lasting, antitumor immunity, involving both CD4 and CD8 
T cells. This effect was attributed to the ability of GM- 
CSF to promote differentiation of dendritic cells, which are 
the most potent APCs for activating both class I and class 
II restricted T cells (Dranoff et al., 1993). 
There was rather complete consensus that a key to in- 
ducing the most potent killing response to tumor seemed 
to be the coactivation of both the CD8+ CTLs and the CD4+ 
Thl cells specific for the tumor. A known CTL determinant 
covalently linked to a T helper determinant and injected 
with either Listeria or IL-12 emerged as one effective way 
to achieve this scenario. Injection of a CTL epitope along 
with a helper epitope in combination with Listeria or IL-12 
seemed a reasonable alternative. D. Pardoll (Johns Hop- 
kins University, Baltimore) described an experiment, done 
in collaboration with Y. Paterson (Johns Hopkins Univer- 
sity, Baltimore), in which simple immunization with Listeria 
expressing a model tumor antigen induced regression of 
established palpable tumors expressing the model anti- 
gen (Pan et al., 1995). They postulate that this is due to 
the sequential residence of Listeria in both the class I and 
class II compartments of a macrophage, which could pos- 
sibly induce efficient peptide loading into both the MHC 
class I and class II pathways. 
Do self-peptides associated with tumors actually induce 
T/B cell responses in real life? This was answered by M. 
Cheever (University of Washington, Seattle), whose group 
has shown that some patients with breast cancer have an 
existent immune response to HEFQ/neu. T cells specific 
for peptides of HER-2/neu have also been demonstrated 
by Peoples et al. (1995) in patients with breast and ovarian 
cancers. HER-Plneu is a growth factor receptor homolo- 
gous to epidermal growth factor receptor, which is overex- 
pressed in 25%-30% of patients with breast cancer as 
well as some patients with colon, pancreas, gastric, and 
ovarian cancer. Tumor cells from breast cancer patients 
display a 40. to 50-fold excess of this molecule relative to 
the very low levels in normal tissue, making this a target 
self-molecule of choice for raising a possible therapeutic 
target for antitumor autoimmune response. In patients with 
overexpressed HERBlneu, both T cells and immunoglob- 
ulins reactive to HER&?/neu could be demonstrated, thus 
indicating that self-tolerance has been circumvented. Ro- 
dent studies have identified vaccine regimens capable of 
inducing anti-HER-2/neu immune responses in naive 
hosts. Rat and human HER-PIneu proteins are highly ho- 
mologous (89%). Immunization of rats with 15-mer pep- 
tides identical to the natural sequence of both rat neu and 
human HER-2/neu proteins elicited immunity specific for 
both proteins. Clearly, no significant self-tolerance had 
been established toward many determinants on this self- 
protein. Others have used peptides from different tumor- 
related self-proteins such as p53 (Yanuck et al., 1993) or 
Ras (Peace et al., 1994) and found them highly immuno- 
genic. 
Fortunately, it is not always necessary to identify the 
effective cryptic peptide determinants on the self-proteins 
in order to induce an effective immune response. For ex- 
ample, with the self-antigen tyrosinase in a vaccinia virus 
construct, P. Greenberg (University of Washington, Seat- 
tle) was able to elicit both CD4 and CD8 antitumor T cell 
clones in melanoma patients of six different haplotypes. 
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In a study by C. Melief (University Hospital, L&den, The 
Netherlands) with avirally induced tumor, vaccination with 
the whole tumor induced a vigorous CD8+ T cell response 
to two codominant adenovirus determinants. Surprisingly, 
treatment with these peptides resulted in enhancement 
of tumor growth, presumably because of down-regulation 
or competition with a more efficacious response induced 
by the tumor to the same determinants. In contrast, Melief 
reported another example using the human papilloma vi- 
rus 18 (HPV-18)-induced tumor, where vaccination with 
the whole protein (recombinant oncoprotein E7 in a vac- 
cinia virus vector) or the tumor itself failed to raise any 
immune response at all. However, vaccination with the 
right peptides of E7 consistently raised protective T cell 
immunity, thus pointing to the significance of trying hetero- 
geneous strategies, including use of both the whole pro- 
teins or their cryptic peptides (or both) to raise effective 
immunity. 
One proponent of exploring the humoral as well as the 
T cell-mediated arms of the immune response in the fight 
against tumors is H. Wigzell (Karolinska Institute, Stock- 
holm). He reported results from a Swedish study of colo- 
rectal carcinoma patients treated with a monoclonal anti- 
body (MAbl) against a cell surface glycoprotein epithelial 
cell adhesion molecule (EPCAM) overexpressed by colo- 
rectal carcinoma cells. Riethmuller et al. (1994) previously 
reported that treatment with this antibody alone prevents 
micrometastasis in such patients, and now in two cases, 
when administered along with GM-CSF, complete remis- 
sion resulted. Interestingly, Wigzell and colleagues also 
administered anti-idiotypic antibody (Ab2, recognizing 
MAbl) in an alum adjuvant in six of their colorectal carci- 
noma patients, with a very positive clinical outcome in 
each. Of these patients, five not only made an antibody 
(Abl’) that recognized Ab2, but furthermore induced a T 
cell response (delayed-type hypersensitivity [DTH] mea- 
sured by skin granulomas, in vitro IL-2, and interferon-y 
[IFNy] synthesis) specific for EPCAM. As Ab2 images of 
self-antigens may be subjected to unique processing and 
network regulation quite distinct from that of the antigens 
per se, it remain8 a task for the future to determine the 
efficacy and possible exploration of this approach. 
Why some patients have cancer despite an immune re- 
sponse to tumor antigens is probably due to a multitude of 
factors. Survival of many tumors in the face of measurable 
antitumor cellular activity (much as in parasite systems) 
underlines the importance of regarding the living tumor 
as more than an aggregate of tumor cells. The tumor can 
help to establish its own microenvironment by altering the 
expression of MHC molecules or the levels of other activi- 
ties affecting immune induction, such as peptide trans- 
porter molecules, thus preventing the display of peptide 
determinants on their cell surface. We must learn details 
about the local milieu of the tumor, trafficking of cells in 
and out, the true nature of tumor-infiltrating lymphocytes 
(TILs), and APCs at sites of tumor deposition in order to 
exploit methodologies to skew responsiveness at the tu- 
mor sites in the desired direction. 
At the other end of the spectrum, induction of antitumor, 
antiself-immune reactivity could cause simultaneous auto- 
immune pathogenesis: this was another obvious concern 
that was discussed at length in this meeting. A majority 
of self-antigens that have been described as target anti- 
gens for antitumor T cells are expressed at varying levels 
by normal tissue. For example MAGE-1 and MAGE3 are 
expressed in testes, MART-l/As and gplO0 are synthe- 
sized in the retina and normal melanocytes (reviewed by 
Houghton, 1994) and HER-2lneu is expressed at lower 
levels in all tissues. Several strongly encouraging results 
were described in this regard. In a study reported by Kawa- 
kami et al. (1994) patients after having received in vitro 
expanded melanoma-specific TlLs that recognize pep- 
tides from gp100, Melan-A-MART-l, or both, although 
showing a sporadic occurrence of vitiligo did not show 
any adverse ophthalmologic effects. Depigmentation is 
reported to be associated with a good prognosis in mela- 
noma patients, an indication that T cells were successful 
in attacking the tumor. A similar report has been made of 
a patient who, after having received tyrosinase-specific 
TlLs, developed neither depigmentation nor any retinal 
damage (Visseren et al., 1995). In a Johns Hopkins Univer- 
sity trial, renal carcinoma patients, after having received 
GM-CSF-transduced tumor cell vaccine, showed a DTH 
reaction not only against the renal carcinoma cells but 
also against normal epithelium derived from the unaf- 
fected kidney: there was, however, no functionally appar- 
ent autoimmune damage to the normal kidney in these 
patients (D. Pardoll). Analogous results were reported by 
Greenberg and colleagues who constructed transgenic 
mice expressing an envelope (env) protein of Friend mu- 
rine leukemia virus under the regulatory genetic elements 
of immunoglobulin (Hu et al., 1993) albumin, or myosin 
to direct tissue-specific expression of env in lymphocytes, 
liver, and muscle. The env protein is expressed at high 
levels by a Friend virus-induced erythroleukemia (FBL) 
of 88 origin. These env-transgenic mice were tolerant to 
the (whole) env protein. However, adoptive transfer of env 
antigen-specific T cells (derived from nontransgenic mice) 
into the transgenic mice that harbored FBL resulted in 
complete eradication of FBL without any sign of autoim- 
mune injury in any of the lymphoid (Hu et al., 1993) or 
other tissues expressing env. The lack of autoimmune 
damage did not reflect lack of envexpression in transgenic 
lymphocytes for recognition by T cells, since transgenic 
lymphocytes functioned effectively in vitro as stimulators 
for env-specific T cells. The relatively increased level of 
expression of these immunogenic determinants in the tu- 
mor cells accompanied by unique inflammatory conditions 
existing at the tumor site may account for this selective 
tumor-specific destruction. These data seem consistent 
with recent experimental evidence that both a critical den- 
sity of MHC-peptide complexes as well as a critical set 
of costimulatory/accessory molecules is necessary to acti- 
vate T cells; in the absence of these signals, T cells either 
fail to respond or become anergic. The challenge ahead 
is to define these signals further and to learn to manipulate 
them toward a beneficial immune response in the cancer 
patient. 
What would be an intelligent strategy for choosing the 
self-peptides (or mutant self-peptides) expressed on the 
tumor cell that are likely to most effectively immunize 
the host to make a specific assault on the tumor? The 
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current choice is to use peptide determinants that are rec- 
ognized by T cells that are readily isolated from the cancer 
patient. This ensures that the peptide binds to the MHC 
and that the peptide-specific T cell repertoire exists in the 
individual. A. Coutinho (Institut Pasteur, Paris) and I. Co- 
hen (Weismann Institute, Rehovot, Israel) emerged as pro- 
ponents of considering a second level of complexity aris- 
ing for example from the T cell receptor (TCR)-centered 
regulatory circuitsof the immune system (see below). They 
postulated that prior encounters of regulatory circuits with 
different internal and external stimuli will affect the out- 
come of an immune response. This proposition is consis- 
tent with the notion expressed earlier by A. Mitchison 
(Deutsches Rheuma Forschungszentrum, Berlin) that “ev- 
ery gene in the body is an immune response gene” with 
a potential influence on immune responsiveness: these 
gene products could be enzymes involved in processing, 
surface adherence molecules, cytokine genes and recep- 
tors, et cetera, and genetic regulatory elements controlling 
their expression. 
Most experimentally induced autoimmune diseases are 
self-limiting, and Cohen focused on this issue in the con- 
text of his view of the coordinated TCRcentered immune 
regulation of self-recognition (reviewed by Cohen, 1992). 
The organism has developed a natural, vigorous self- 
reactivity toward a key group of self-antigens and determi- 
nants, precisely so that it can focus regulatory cells capa- 
ble of recognizing target structures on the TCRs of the 
effector population. Myelin basic protein (MBP), heat 
shock protein, and tyrosinase are three examples of such 
antigens, as normal individuals have benign self-reactivity 
to these proteins. These TCR-centered regulatory circuits 
have been characterized using MBP in both mouse and 
rat models: mouse and rat T cells specific for MBP use 
conserved a and 8 chains (reviewed by Nanda and Ser- 
carz, 1993) in their TCR structures. The connectivity of 
these MBP-reactive T cells to regulatory circuits was re- 
vealed by the demonstration that peptides of their TCR 
structures (without introduction of MBP in the animal) can 
activate CD4 and CD8 regulatory cells and prevent subse- 
quent activation of T cells specific for MBP (reviewed by 
Kumar and Sercarz, 1993). A similar interpretation was 
offered for an experiment from Melief’s laboratory: an ex- 
cellent tumor-specific response could be induced by im- 
munizing the host with irradiated tumor cells expressing 
~53, and the antitumor T cells in this host recognized a 
wild-type peptide of ~53. However, if the animal were im- 
munized with the same peptide, no antitumor CTL re- 
sponse was raised. One explanation for this could be 
involvement in a hard-wired circuit resulting in activation 
of a strong down-regulatory system upon its introduction. 
Another explanation for the result of the p83 experiment 
of Melief’s could be that the particular peptide chosen for 
vaccination might have had partially antagonistic proper- 
ties in signaling the TCR. The interaction of antagonists 
and partial agonists of the TCR has already been consid- 
ered as a regulatory device (P. Allen, Washington Univer- 
sity, St. Louis) in autoimmune contexts (reviewed by Sette 
et al., 1994). In the context of an antitumor response, it 
is perhaps worthwhile to plan to inhibit crucial regulatory 
populations while simultaneously seeking very strong ago- 
nists that would energetically activate the T cell system. 
Passive immunization with tumor-specific CD8 T cells 
along with IL-2 as a cytokine to replace CD4 helpers is a 
more traditional strategy (described above) that is suc- 
cessfully being used in cancer patients. Greenberg is in- 
vestigating several sophisticated avenues in this area. 
One strategy (being pursued with S. Lupton, Targeted 
Genetics, Seattle is to transfect the CD8 T cells directed 
against the tumor with the IL-2 gene linked to the regula- 
tory elements of genes that get activated upon target rec- 
ognition, such as IFNy. This would result in IL-2 production 
following encounter with the tumor in CD8 transfectants 
with the hybrid IL-2 gene. The tumor-specific CD8 T cells 
would thus be propagated upon activation, resulting in 
maintenance of effective immunity against the tumor with- 
out the requirement for CD4 helper T cells or potentially 
toxic exogenous 11-2. Another highly efficient avenue they 
have pursued is to construct chimeric growth factor recep- 
tor molecules in which the extracellular domains of the a 
and 8 chains of the GM-CSF receptor are linked to the 
cytoplasmic domains of 8 and y chains, respectively, of 
the IL-2 receptor (Nelson et al., 1994). CD8 T cells normally 
do not have receptors for GM-CSF, but upon activation 
they produce GM-CSF. The CD8 transfectants that ex- 
press the chimeric receptor chains can proliferate to GM- 
CSF as a result of intracellular signaling via its IL-2 moiety, 
thus rendering GM-CSF as a potential autocrine growth 
signal. Additionally, transfectants made using either of the 
above strategies can also be constructed to contain a sui- 
cide gene, thymidine kinase (HSV-TK), that can be used 
to ablate these CD8 cells in vivo when the job of tumor 
eradication is complete, to avoid autoimmune damage 
caused were there to be CD8’ T cell reactivity for self- 
antigens. 
Closing Remarks 
It was evident from the discussion at the workshop that 
students of autoimmunity, parasite immunity, and tumor 
immunity have many shared interests. How self-destructive 
T cells became initially activated and propagated during 
the autoimmune disease still defies explanation. It is, how- 
ever, being actively studied, and a solution to this puzzle 
should be readily adaptable to the cancer problem. Aside 
from virus-induced tumors, effective immunization against 
tumors represents an activation of natural autoimmunity 
to a set of self-antigens that had not induced tolerance 
during development or in the periphery. In the same vein, 
parasites, perhaps just like tumors, seem to create a bar- 
rier: they escape in the face of specific and fully capable 
T cells. Understanding the nature of this barrier may reveal 
what needs to be overcome in the cancer patient to allow 
the activation of T cell responses specifically to kill the 
tumor. Thus, the task ahead is to exploit the resource of 
the protected, nontolerized T cell repertoire and to learn 
how responses within it can be fostered by appropriate 
antigen presentation and costimulation. To paraphrase 
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Pogo, “we have identified the enemy and it is us!” What 
is left is to seduce the available immune repertoire into 
effective action. 
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